Skip to main content

Advertisement

Log in

Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics

  • New Antimicrobial Agents
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The dependence of the antibacterial activity of the two oral cephalosporins cefixime and cefaclor on pharmacokinetic properties was investigated in an in vitro model using strains of enterobacteria and a streptococcal strain. In the cultures the course of serum concentrations of the respective antibiotic was simulated. The more rapidly attained (1 h) high peak levels (17.5 µg/ml) of cefaclor (500 mg dose) in no case showed an advantage over the more slowly reached (3 h) low peak levels (2.5 µg/ml) of cefixime (200 mg dose). Cefixime was comparable to cefaclor with respect to its initial killing velocity, whereas it was generally superior with respect to maximum values for reduction of bacterial counts. Due to its long elimination half-life (2.5 h) cefixime prevented regrowth for at least twice as long as cefaclor, which has a short half-life (0.7 h). As a result of its antibacterial activity and pharmacokinetic properties cefixime can be administered less frequently than cefaclor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Neu, H. C., Chin, N.-X., Labthavikul, P.: Comparative in vitro activity andβ-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrobial Agents and Chemotherapy 1984, 25, 174–180.

    Google Scholar 

  2. Brittain, D. C., Scully, B. E., Hirose, T., Neu, H. C.: The pharmacokinetic and bactericidal characteristics of oral cefixime. Clinical Pharmacology and Therapeutics 1985, 38: 590–594.

    PubMed  Google Scholar 

  3. Faulkner, R. D., Yacobi, A., Barone, J. S., Kaplan, S. A., Silber, B. M.: Pharmacokinetic profile of cefixime in man. Pediatric Infectious Disease Journal 1987, 6: 963–970.

    PubMed  Google Scholar 

  4. Brogard, J. M., Comte, F.: Pharmacokinetics of the new cephalosporins. In: Schönfeld, H. (ed.): Antibiotics and chemotherapy, Volume 31, Pharmacokinetics II. S. Karger, Basel, 1982, p. 145–210.

    Google Scholar 

  5. Deutsches Institut für Normung e.V.: Methoden zur Empfindlichkeitsprüfung von bakteriellen Krankheits-erregern (außer Mykobakterien) gegen Chemotherapeutika. DIN 58 940 Teil 5. Beuth Verlag, Berlin, 1979.

    Google Scholar 

  6. Grasso, S., Meinardi, G., De Carneri, I., Tamassia, V.: New in vitro model to study the effect of antibiotic concentration and rate of climination on antibacterial activity. Antimicrobial Agents and Chemotherapy 1978, 13: 570–576.

    PubMed  Google Scholar 

  7. White, C. A., Toothaker, R. D., Smith, A. L., Slattery, J. T.: Correction for bacterial loss in in vitro dilution models. Antimicrobial Agents and Chemotherapy 1987, 31: 1859–1860.

    PubMed  Google Scholar 

  8. Drusano, G. L.: Role of pharmacokinetics in the outcome of infections. Antimicrobial Agents and Chemotherapy 1988, 32: 289–297.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nies, B.A. Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics. Eur. J. Clin. Microbiol. Infect. Dis. 8, 558–561 (1989). https://doi.org/10.1007/BF01967481

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01967481

Keywords

Navigation